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1. Introduction 
Over the years a wealth of information on the role played by transcription factors in 
myeloid biology has contributed to our understanding of both normal and abnormal 
myeloid development. However, the regulation of mRNA translation in myeloid cell 
maturation has, in comparison, been a neglected area of study. A better understanding of 
the translational control of myeloid gene expression will undoubtedly provide important 
insights into both normal and abnormal myeloid maturation. This chapter summarizes our 
current understanding of the regulation of myeloid gene expression at the mRNA 
translational level and delineates levels of disruption in myeloid disease, with an emphasis 
on leukemias. 
2. Myeloid differentiation and neutrophil development 
During hematopoiesis, granulocytes and monocytes arise from a common progenitor cell in 
the bone marrow and differentiate in response to cytokines and transcription factors 
ultimately giving rise to mature neutrophils and monocytes in the circulation. The 
granulocyte progenitor cells pass through several identifiable maturational stages, during 
which they acquire the morphologic appearance and granule contents that characterize the 
mature granulocyte(Rev in(Berliner, 1998)). The earliest identifiable granulocyte precursor is 
the myeloblast, which is characterized by very few granules, little cytoplasm and a 
prominent nucleolus. Transition to the promyelocyte stage is associated with the acquisition 
of primary granules. Primary granules are found in both granulocytes and monocytes and 
contain many of the proteins necessary for intracellular microbicidal activity (Bainton, 1975). 
The transition to the myelocyte stage is associated with the acquisition of secondary or 
“specific” granules(Bainton, 1971). Myelocytes further mature to give rise to bands and 
mature neutrophils. The appearance of secondary granules and their content proteins, 
provides a unique marker of commitment to terminal neutrophil differentiation (reviewed 
in (Borregaard et al., 2001)). Several lines of evidence from our laboratory have established 
that the expression of the secondary granule protein (SGP) genes, which are functionally 
diverse and physically unlinked, is coordinately regulated at the level of mRNA 
transcription (reviewed in(Berliner, 1998)). Absence of SGP gene expression is a consistent 
abnormality in Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).  
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2.1 Transcriptional control of myeloid maturation 
Maturation of myeloid progenitor cells into specialized blood cells that play a vital role in 
innate immunity, is regulated by a well-orchestrated interplay of transcription factors 
(Tenen, 2003). Recent studies have delineated transcription factors that contribute to the 
process of maturation. These include a  category of factors termed “master regulators” of 
lineage development and include PU.1, and CCAAT enhancer-binding protein- 
(C/EBP) (Tenen, 2003). These factors not only promote lineage-specific gene expression 
but also suppress alternative lineage pathways. For example, Laslo et al (Laslo et al., 2006) 
elegantly demonstrated that cell fate determination is dependent upon subtle changes in 
expression levels of transcription factors, which regulate differential lineage maturation. 
Levels of PU.1 expression are increased by Egr-1/Nab-2 in developing 
monocytes/macrophages; while Egr-1 simultaneously represses the expression of the 
neutrophil specific Gfi-1 transcription factor (see below), thereby repressing the 
neutrophil development program. 
2.1.1 C/EBP 
C/EBP has been recognized to be a master regulator of the granulopoietic developmental 
program. It is expressed at high levels throughout myeloid differentiation (Tsukada et al., 
2011). C/EBP binds to the promoters of multiple myeloid-specific genes, thereby 
regulating gene expression at many different stages of myeloid maturation. C/EBP mice 
die perinatally due to defects in gluconeogenesis that result in fatal hypoglycemia, and 
demonstrate an early block in the differentiation of granulocytes without affecting either 
monocyte/macrophage maturation or the differentiation of other hematopoietic lineages. 
The expression of C/EBP is associated with growth arrest and differentiation of 
granulocyte precursor cells. This block in proliferation is thought to occur via the interaction 
of C/EBP with cyclin-dependent protein kinases (cdk2 and cdk4), resulting in a block in 
cell proliferation. In addition, C/EBP inhibits E2F-dependent transcription, which also 
contributes to inhibition of cell proliferation and induction of differentiation associated with 
C/EBP-induced granulopoiesis (Timchenko et al., 1997; Timchenko et al., 1999) 
2.1.2 PU.1 
A second master myeloid regulator  PU.1, is a member of the Ets family of transcription 
factors and is expressed  in both B cells and monocyte/macrophages (Chen et al., 1995). PU.1 
is also expressed at lower levels in granulocytes and eosinophils as well as in CD34 
hematopoietic progenitor cells. High levels of PU.1 expression in fetal livers of mice 
preferentially directs monocyte/macrophage development, whereas low levels of PU.1 
result in B-cell development (DeKoter and Singh, 2000). Studies have revealed that 
downregulation of c-Jun, a coactivator of PU.1, by C/EBP is necessary for granulocytic 
maturation and is the mechanism through which C/EBP blocks macrophage development 
(Rangatia  et al., 2002). Gene knockout studies of PU.1 in mice resulted in perinatal lethality 
accompanied by the absence of mature monocytes/macrophages, B cells as well as and 
delayed and reduced granulopoiesis (Scott et al., 1994). Following in vitro differentiation, 
embryonic stem (ES) cells derived from PU.1 blastocysts fail to express mature myeloid 
cell markers, suggesting that PU.1 is not essential for the initial events associated with 
myeloid lineage commitment but is necessary for the later stages of development. 
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2.1.3 Growth Factor Independence-1 (Gfi-1) 
Gfi-1 is a highly conserved transcriptional repressor that encodes a 55kD nuclear proto-
oncogene that is composed of six zinc finger domains at the carboxy terminus and a N-
terminal SNAG  or repression domain (rev in (van der Meer et al., 2010). Gfi-1 is expressed at 
high levels in the thymus and bone marrow, while its paralog Gfi1B, is expressed in the bone 
marrow and spleen. An essential role of Gfi-1 in neutrophil differentiation became apparent 
following reports of gene disruption in mice (Hock et al., 2003). Gfi1-null mice are severely 
neutropenic and eventually succumb to bacterial infections. These mice lack mature 
neutrophils and their granulocyte precursors are unable to differentiate into mature 
neutrophils and also lack expression of specific granule proteins (SGPs). In addition, Gfi-1 
bone marrow expresses atypical Gr1Mac1 myeloid precursor cells that appear to have 
characteristics of both granulocyte and macrophage precursors. These observations confirm a 
critical role for Gfi-1 in the neutrophil maturation program. Work from our laboratory has 
shown that Gfi-1 synergizes with another member of the CCAAT enhancer binding protein 
family of transcription factors, C/EBP to transactivate the promoters of late myeloid genes. 
This synergy is lost in a patient with specific granule deficiency (SGD), who has a 
heterozygous substitution mutation in the C/EBP gene as well as decreased levels of Gfi-1 in 
the bone marrow (Khanna-Gupta et al., 2007). Heterozygous dominant negative mutations in 
the Gfi-1 gene have been described in two patients with severe congenital neutropenia (SCN) 
(Person et al., 2003), thus emphasizing the role of Gfi-1 in the neutrophil maturation pathway.  
Over the years a great deal of information pertaining to the transcriptional regulation of 
myeloid development has become available and has aided in our understanding of the 
process of granulopoiesis and how it goes awry in myeloid leukemias. In contrast, as 
outlined below, the role of mRNA translation in the process of normal  myeloid 
development is only just beginning to be understood (rev in (Khanna-Gupta, 2011)) 
3. An overview of the process of mRNA translation in eukaryotic cells 
Eukaryotic protein synthesis involves the coordinated interplay of hundreds of 
macromolecules such as mRNAs, tRNAs, activating enzymes, protein factors and 
ribosomes. Ribosomes are the protein synthetic factories upon which protein synthesis 
proceeds and are composed of a large (60S) and a small (40S) subunit. Each of these subunits 
is composed of two-thirds RNA and one-third protein. Protein synthesis occurs on the 
ribosome in three phases: translation initiation, elongation and termination. Regulation of 
gene expression takes place primarily at the initiation stage which therefore is the rate-
limiting step in protein synthesis. The delicate balance of events leading to protein 
expression is critical for cellular growth, proliferation, differentiation and apoptosis (Rev in 
(Van Der Kelen et al., 2009)). In eukaryotes, translation  initiation factors (eIFs) play a crucial 
role in the dissociation of 40S and 60S ribosomal subunits thus  enabling  recruitment of 
mRNA and initiator tRNAs to the 40S subunit followed by interaction with the 60S subunit 
resulting in the reformation of the 80S ribosome allowing for  elongation and termination of 
the polypeptide chain to ensue (rev in (Van Der Kelen et al., 2009)). 
3.1 Control of translation initiation 
The first step in the translation of mRNA in eukaryotic cells begins with the binding of the 
40S small ribosomal subunit to the 5’ end of the mRNA to be translated in the process of 5’ 
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cap-dependent translation. Cap-binding protein eukaryotic initiation factor 4E (eIF4E) 
recognizes and binds to the m7GpppN cap (where m is a methyl group and N any 
nucleotide) structure at the 5’end of the mRNA to be translated. Under normal physiologic 
conditions, eIF4E strongly associates with 4E-binding proteins (4E-BPs) thus preventing 
eIF4E from initiating protein synthesis, this represents the first rate limiting step in the 
process of protein synthesis. This inhibition is overcome by the phosphorylation of 4E-BPs 
via signal transduction pathways (involving PI3K and mTOR among others, see below) that 
are regulated by growth factors and nutrient status of the cell, thus causing 4E-BPs to be 
phosphorylated and to dissociate from eIF4E (Figure 1). This enables a competing adapter 
molecule eIF4G, to bind to eIF4E. eIF4G  then recruits the ATP-dependent RNA helicase 
eIF4A (eIF4E, 4G and 4A are collectively referred to as eIF4F in the literature), the 
ubiquitously expressed cofactor eIF4B as well as eIF3, a multisubunit initiation factor, all of 
which bind to the 5’ cap region of the mRNA, thus setting the stage for mRNA translation to 
begin (rev in(Sonenberg and AG., 2009)).  
 
Fig. 1. Under basal conditions eIF4E is tightly bound to 4E-BPs. When cells are under stress 
or nutrient deprived, Phosphorylation of 4E-BPs is triggered by P13K (Phospho-inositol 
Kinase) and mTOR, which causes the 4E-BPs to be phosphorylated and/or to have reduced 
affinity for eIF4E. eIF4E is now free to bind eIF4G to initiate mRNA translation. 
Translation initiation however requires the small ribosomal subunit 40S to be complexed 
with the so called ternary complex before it associates with the mRNA (Figure 2). The 
assembly of the ternary complex, consisting of the G protein eIF2B, eIF2, the initiator tRNA, 
tRNAi met and GTP, is the second rate-limiting step in mRNA translation. Recognition of the 
first AUG codon in the mRNA to be translated followed by initiation of protein synthesis is 
dependent on this process. Upon recognition of the first in-frame AUG, eIF2-GTP is 
hydrolyzed and the resulting eIF2-GDP is restored to eIF2-GTP by the guanine-nucleotide-
exchange factor known as eIF2B to continue another round of translation initiation (Figure 
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2). This process is inbibited when the  subunit (S51 residue) of eIF2 is phosphorylated. This 
is brought about by the activation of a number of eIF2 kinases which are activated under 
conditions of cellular stress and aid in the reduction of protein synthesis until the stressful 
circumstance has passed (Figure 2). If stress remains unabated, apoptosis ensues. EIF2 
kinases include the Heme-regulated inhibitor kinase (HRI), RNA-dependent protein kinase 
(PKR), PKR-like endoplasmic-reticulum kinase (PERK) and mGCN2(mammalian general 
control non-derepressing) (rev in (Raven and AE., 2008) and (Chen, 2007) and references 
therein). Since phosphorylated eIF2 has a higher affinity for eIF2B than eIF2, 
phosphorylation of even a small percentage of eIF2 can lead to a reduction in protein 
synthesis. Phosphorylation of eIF2 can be reversed upon removal of the phosphate group 
by specific phosphatases thus restoring the cell to homeostasis (Harding et al., 2009). 
 
Fig. 2. During initiation, a GTP molecule is hydrolyzed to GDP which is then recycled by 
eIF2B, making eIF2-GTP available for the continuation of the synthesis cycle. However, 
under cellular stress conditions, alterations in nutrient status, growth factors, mitogens and 
inducers of differentiation a variety of a eIF2 kinases are activated which causes the 
phosphorylation of eIF2 which has an increased affinity towards eIF2B. This traps 
available eIF2 and eIF2B resulting in a block in protein synthesis. 
Formation of the 43S preinitiation complex occurs once the ternary complex binds to the  
40S subunit complexed with eIF3 and eIF1A. The pre-initiation complex further associates 
with the mRNA through eIF3 and eIF4G, thus forming the 48S initiation complex. mRNA 
scanning begins when the 40S subunit moves along the mRNA in a 5’ to 3’ direction. Upon 
encountering the first in-frame translation initiation codon AUG, a codon (mRNA) – 
anticodon (tRNA) recognition is established resulting in the dissociation of initiation factors 
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from the 40S subunit. This enables the binding of the 60S subunit resulting in the assembly 
of the functional ribosome (80S) and for peptide elongation to proceed.  
The 3’ end of the mRNA together with a number of the initiation factors ensure the 
stabilization of ribosome-mRNA interaction. Poly (A) tail and polyA binding protein (PABP) 
interact with eIF4G to form a pseudo-circular mRNA. This structure is thought to reduce the 
translational error rate as translation from intact RNAs alone would be permitted. This 
mRNA configuration also gives the initiation factors the necessary spatial proximity that 
ensures efficient dissociation and re-association capabilities to permit another round of 
protein synthesis to occur. 
3.2 The mTOR pathway 
mTOR (mammalian/mechanistic target of rapamycin) is involved in an evolutionarily 
conserved pathway that is critical for cellular responses to environmental cues. mTOR  is a 
serine/threonine protein  kinase belonging to the phospho inositide 3-kinase (PI3K)-related 
protein kinases (PIKK) family of protein kinases, which consists of a protein complex that 
enable organisms to cope with metabolic, environmental and genetic stresses (rev in (Sengupta 
et al., 2010)). Mammalian TOR forms two structurally and functionally distinct  multiprotein 
complexes, mTORC1: in which mTOR is complexed with Raptor (the regulatory protein of 
mTOR), LST8 (also called GL) and PRAS40 (proline-rich Akt/PKB substrate 40kDa), and 
mTORC2, harboring both LST8 and Rictor (rapamycin-insensitive companion of mTOR). Only 
mTORC1 is responsive to the inhibitory effects of the antibiotic rapamycin (Figure 3) 
(Wullschieger et al., 2006). When activated, mTORC1 functions to regulate protein synthetic 
pathways in response to nutritional, environmental and growth factor mediated signals. The 
TCS1 and TCS2 (tuberous sclerosis 1 and 2) proteins form a tumor suppressor complex that 
transmits signals to mTORC1 by regulating the activation of Rheb (Ras homolog enriched in 
brain; a GTP-GDP exchange protein). The TCS1 and TSC2 complex regulates the GTP-loading 
state of Rheb. GTP-bound Rheb interacts with mTORC1 and renders it active. The two major 
targets of mTOR are the 4E-BPs (see Figure 1) and the 40S ribosomal protein S6 kinase (S6K1), 
both important components of the translational machinery (Figure 3). 
Upon activation, mTORC1 regulates the phosphorylation/activation of p70 S6 kinase  
(S6K1) and the phosphorylation/deactivation of 4E-BP1(Platanias, 2005). Activation of S6 
kinase modulates ribosome biogenesis through the activation of ribosomal protein S6 
(rpS6)(Lee-Fruman et al., 1999) (Figure 3). S6K1 also phosphorylates eIF2B, SKAR (S6K1 
Aly/REF-like target) and eukaryotic elongation factor 2 kinase, thus affecting both the 
initiation and elongation stages of mRNA translation. 
As described above, hypo-phosphorylation of the 4E-BPs increases their affinity for eIF4E, 
thus blocking the interaction of eIF4G and eIF4A thereby hampering translation initiation of 
mRNA from proceeding (Figure 1). However,  phosphorylation of the 4E-BPs by activation 
of  the mTORC1 signaling pathway (Figure 3) results in  lowered affinity of these proteins 
for eIF4E, thus allowing for the formation of the competing eIF4E-eIF4G-eIF4A (eIF4F)- 
mRNA  complex  that permits mRNA translation to proceed(Gingras et al., 2001). Thus 
inhibition of mTORC1 activity results in the down regulation of the activity of several 
components of the translational machinery resulting in a block in cell proliferation and 
eventually to cell death. 
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Fig. 3. mTOR pathway. See text for details 
4. Translation control in Myeloid cells 
While the general principles of mRNA translation hold in myeloid cells,  it has been shown 
that when 4E-BP1 and 4E-BP2 genes were knocked out in mice an impairment of 
myelopoiesis was observed with no obvious effect on thymocyte maturation(Olson et al., 
2008). An increase in the number of immature granulocytic precursors and a decrease in the 
numbers of mature granulocytes was observed in these mice compared to their wild type 
littermates. Other studies have shown that expression of the 4E-BPs is significantly 
increased during granulopoiesis(Grolleau et al., 1999). It was thus concluded that 4E-BP1 
and 4E-BP2 play an important role in the early phases of granulo-monocytic differentiation 
thereby highlighting a critical role for translation initiation during granulopoiesis. It should 
be noted that 4E-BP1 has been shown to be constitutively phosphorylated in both chronic 
myeloid leukemia  (CML) and in acute myeloid leukemia (AML) due to the constitutive 
activation of mTOR and Bcr-Abl in CML(Ly et al., 2003) and PI3K-Akt in AML(Xu et al., 
2003). 
4.1 Translational defects in myeloid leukemias 
Activation of aberrant transcriptional and signaling pathways leading to enhanced survival 
and proliferation of leukemic progenitors is a hallmark of acute myeloid leukemia (AML) 
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(Scholl et al., 2008; Tenen, 2003). The recent past has seen marked changes for the better in 
our understanding of the biology underlying AML. Based on these advances, targeting 
overactive signaling pathways in transformed cells has become an active area of research 
with the ultimate goal of finding molecules that specifically target only the transformed cell.  
4.1.1 mTOR 
The mTOR pathway has been shown to be activated in a number of cancers including AML 
(rev in (Tamburini et al., 2009a)). In fact, mTORC1 has been shown to be activated in over 
90% of primary AML samples (Tamburini et al., 2009b). There has thus been a great effort to 
demonstrate the efficacy and use of Rapalogs, a class of drugs that include the mTORC1 
inhibitor Rapamycin (see Figure 3) and RAD001, as anti-cancer agents. However, despite the 
anticipated cell death that blocking the mTORC1 pathway should result in, it has been 
demonstrated that the anti-leukemic effects of rapalogs are merely cytostatic. This is likely 
due to the fact that mTORC1 inhibition by rapalogs results in the activation of a number of 
feedback loops involving leukemogenic kinases such as P13K and ERK, thus limiting the 
anti-leukemic effects of this class of drugs.(Wang et al., 2008) 
4.1.2 Oncogenic mRNAs  
The translation efficiencies of different mRNAs are dependent partly on the structural 
complexity of their 5’UTR (untranslated region). mRNAs with simple or short 5’UTRs,  such 
as in the actin mRNA, are translated with high efficiency even in untransformed cells. 
However, mRNAs harboring long and complex 5’UTRs are generally translated with low 
efficiency and are referred to as “weak” mRNAs because of weak interactions with the eIF4F 
translation initiation complex (see above). In transformed cells on the other hand, this 
interaction improves due to the increased activity of eIF4F leading to increased translation 
of the weak mRNAs. It is noteworthy that a number of these weak mRNAs have oncogenic 
potential because they encode proteins involved in cell cycle regulation (e.g. cyclin D1) DNA 
replication (ornithine decarboxylase) and other pathways (c-myc, VEGF, Bcl-2, survin),  all of 
which contribute to cell survival and proliferation. Expression of such mRNAs is regulated at 
the translational level and their overexpression likely contributes to the transformation process 
in AML ((Tamburini et al., 2009a) and references therein). Since these “oncogenic” mRNAs 
have been found to be more sensitive to translation inhibition, there has been an effort to 
identify compounds that block mRNA translation. An example of such a compound is 4EGI-1 
which is a 4E-BP1 mimetic and potently blocks the interaction of eIF4E and eIF4G during 
translation initiation (see above). 4EGI-1 has been shown to abrogate the expression of c-Myc 
and Bcl-xL, both proteins with oncogenic potential. Additionally, this compound has shown 
therapeutic potential as it induces selective apoptosis in AML blast while allowing normal 
CD34+ hematopoietic progenitors to survive (Tamburini et al., 2009b). 
Overexpression of the initiation factor eIF4E has been described in primary cells derived 
from M4/M5 AML  compared to bone marrow mononuclear cells (Topisirovic et al., 2003). 
EIF4E expression has been known to increase protein synthesis and to transform cells 
(Wendel et al., 2007). It should be noted that the antiviral compound ribavarin has been 
shown to inhibit the activity of eIF4E (Kentsis et al., 2004). In a small study involving 11 
M4/M5 AML patients who were given ribavarin, three patients responded with one in 
complete remission and two in partial remission (Assouline et al., 2009). This study 
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demonstrates that blocking the translational engine could prove to be a very important tool 
in the development of future AML therapeutics. 
5. Translational control of the myeloid master regulator C/EBP 
C/EBP is the founding member of a family of basic region/leucine zipper (bzip) 
transcription factors many of which contribute to granulopoiesis and are regulated at the 
translation level. (Rev in(Fuchs, 2007; Koschmieder et al., 2009; Muller and Pabst, 2006; 
Schuster and Porse, 2006) ). For the sake of simplicity only the translational control of the 
master myeloid regulator C/EBP will be discussed here.  
 
Fig. 4. Structure of the C/EBP mRNA. TE I, II and III are activation domains. bZip is the 
basic leucine-zipper DNA binding domain. 
Profound hematopoietic abnormalities have been reported for mice in which C/EBP is 
ablated(Zhang et al., 1997). The C/EBP gene is intronless and generates two isoforms as a 
result of the differential utilization of alternate translation start codons. The resultant p42kD 
(full length) and p30kD (truncated) C/EBP proteins differ from each other at the N-
terminus, which is shorter in the p30kD protein (Figure 4). Translational control of C/EBP-
isoform  expression occurs via a conserved cis-regulatory uORF (upstream open reading 
frame) in the 5’UTR (untranslated  region) that is out of frame with the coding region of 
C/EBP and is thought to be responsive to the activities of the translation initiation factors  
eIF4E and  eIF2 (Figure 4 and see above). Thus, an increase in the activity of eIF2 or eIF4E, 
results in the increase in expression of the shorter p30 isoform (rev in(Calkhoven et al., 
2000)). An uORF monitors the site of translation initiation by sensing the activity of the eIF2 
and eIF4E. When levels of these factors are high, the out-of-frame uORF (Figure 4, red AUG) 
is translated, but termination of its translation very close to the translational start site (black 
AUG) for p42 is thought to prevent reinitiation at the p42 AUG. Instead, ribosomes continue 
to scan and reinitiate at a downstream AUG (Figure 4, green AUG), resulting in the 
expression of C/EBP p30. In contrast, under basal conditions, when levels of the initiation 
factors are relatively low, most ribosomes do not initiate translation at the uORF but instead 
initiate translation at the p42 AUG by a process involving “leaky ribosome scanning”, 
resulting in translation of the full length  C/EBP p42 isoform(Calkhoven et al., 2000). This 
mechanism of translational control appears to be conserved among key regulatory proteins 
which govern differentiation and proliferation (rev in (Khanna-Gupta, 2011)). 
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High levels of expression of the p30 C/EBP protein  have been shown to  interfere with the 
DNA binding ability of the full length p42 C/EBP, thus  inhibiting transactivation of key 
granulocytic target genes in a dominant-negative manner (Pabst et al., 2001), In addition, p30 
transactivates the expression of a distinct subset of  target genes different from that of the 
full length p42 C/EBP thereby altering their expression (Geletu et al., 2007). Mice 
engineered to express only the p30 C/EBP isoform  resulted in the development of AML 
with complete penetrance (Kirstetter et al., 2008). Thus changes in the ratio of p42:p30 
isoforms of C/EBP play a critical role in contributing to AML(Fu et al., 2010). 
Suppression of C/EBP translation has also been observed in the leukemic blasts of patients 
with CML (chronic myelogenous leukemia). This occurs via an RNA binding protein, 
hnRNP-E2, which binds to the uORF of the C/EBP mRNA, thereby inhibiting translation. 
Expression of hnRNP-E2 is thought to be upregulated by the activity of the oncogenic BCR-
ABL fusion protein in CML patients, and downregulation of hnRNP-E2 by the BCR-ABL 
inhibitor Imatinib results in restoration of C/EBP protein expression and granulocytic 
differentiation of the CML blasts(Perrotti et al., 2002). 
6. Role of microRNAs in translation control 
6.1 General principles 
MicroRNAs (miRNAs) are 18-24 nucleotides long non-coding RNAs that regulate eukaryotic 
gene expression influencing cellular functions as diverse as cell proliferation, differentiation 
and apoptosis. miRNAs are non-coding RNAs which silence target genes post-
transcriptionally  by binding to complementary sequences in the 3’UTR (untranslated region) 
of the target mRNA  resulting in either  mRNA degradation  or translation repression (rev in 
(Ambros, 2004)). More than 100 miRNAs are expressed in the hematopoieteic compartment 
(rev in (Gazzar and McCall, 2011)). MiRNAs are encoded in the genome and are initially 
transcribed by RNA polymerase II as long primary transcripts referred to as primary miRNAs 
(pri-miRNAs). These hairpin transcripts are recognized and processed by RNase III enzymes 
called Drosha and DGCR8 into 60-80 nucleotide intermediates called precursor miRNAs (pre-
miRNAs) which are then exported to the cytoplasm by Exportin 5 where a second 
ribonuclease termed Dicer cleaves the pre-miRNAs to generate double stranded 18-24 
nucleotide long miRNAs. One strand of the miRNA is next destroyed and the remaining 
strand, the guide strand, is then incorporated into the RNA-induced silencing complex or 
RISC, a large protein complex that also contains the Argonaute 2 or mRNA cleaving proteins. 
The miRNA guides the RISC complex to target complementary regions in the 3’UTRs of 
mRNAs, leading to repression of translation or destabilization of the mRNA by deadenylation. 
(rev in (Manikandan et al., 2008)). In mammalian cells,  6-8 nucleotides of the miRNA (known 
as the seed region) base pair with the cognate recognition sequence in the 3’UTR of the target 
mRNA. In general, a perfectly matched sequence between the seed region and mRNA target 
results in degradation of the mRNA target. An imperfect match however, results in translation 
repression (rev in (Gazzar and McCall, 2011)). MiRNAs are thought to repress translation by 
blocking translation initiation of the target mRNA (Filipowicz et al., 2008). 
6.2 miRNAs in myeloid biology 
An increasing body of evidence implicates miRNA activity in mediating both normal and 
abmormal myelopoiesis (rev in (Pelosi et al., 2009) and (Gazzar and McCall, 2011)). 
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Granulocytes arise from the GMPs (granulocyte monocyte progenitors) which are capable of 
developing into granulocytes or monocytes as a result of cytokines  and thus transcription 
factor activation (Dahl R et al., 2003). MiRNAs have been shown to activate or be activated 
by myeloid specific transcription factors such as PU.1, C/EBP and Gfi-1. Mir-223, for 
example, is thought to be a direct target of C/EBP and its expression increases during 
granulopoiesis. C/EBP is a master regulator of  granulopoiesis (Tenen, 2003). Complete 
loss of  mir-223 in mice results in the expansion of granulocyte precursor cells resulting from 
a cell autonomous increase in the number of granulocytic progenitors (Johnnidis et al., 2008). 
In contrast, overexpression of mir-223 in acute promyelocytic leukemia (APL) cells results in 
an enhanced capacity for granulocytic differentiation (Fazi et al., 2005). Mir-223 is thus 
thought to be a positive regulator of granulopoietic differentiation. It has also been shown 
that mir-223 targets E2F1, a master cell cycle regulator, by inhibiting translation of its 
mRNA. Thus, granulopoiesis  appears to be regulated by a C/EBP–miR-223–E2F1 axis, 
where  miR-223 functions as a key regulator of myeloid cell proliferation associated with 
E2F1 in a negative feedback loop(Pulikkan et al., 2010).  
 In a recent study, Eiring et al demonstrated a new “decoy” role for miRNAs involving the 
master reugator C/EBP. They showed that mir-328 is down regulated in myeloid cells of 
chronic myelogenous leukemia (CML) patients in blast crisis. Restoration of mir-328 
expression however rekindles differentiation in the CML blast cells by  a mechanism 
involving the simultaneous interaction of mir-328 with the C/EBP translational inhibitor 
hnRNP-E2 (see above), as well as with the mRNA for PIM1, a survival factor. Since, the 
interaction with hnRNP-E2 occurs independently of mir-328’s seed sequence, this miRNA 
acts as a “sink” for hnRNA-E2 binding allowing for the  release of C/EBPmRNA from the 
negative effects of hnRNA-E2-mediated translational inhibition. Thus mir-328 appears to 
control cell fate by its ability to base pair with the 3’UTR of target mRNAs  (PIM1) as well as 
by acting as a decoy for hnRNP binding resulting in the release of C/EBP from 
translational inhibition, thereby altering cell fate(Eiring et al., 2010). 
Gfi-1 (growth factor independence-1), a transcriptional repressor that promotes granulocytic 
differention, has been shown to regulate the expression of mir-196b (Velu et al., 2009). The 
expression of mir-196b is high in the common myeloid progenitors (CMPs) which can 
differentiate either along the granulocytic or monocytic lineages. Gfi-1 has been shown to 
bind to the promoter of mir-196b thereby repressing its expression and promoting 
granulopoiesis. Additionally, overexpression of mir-196b was shown to block granulopoieis, 
confirming the importance of low level expression of this miRNA in contributing to 
granulopoietic maturation (Hock et al., 2003) . 
PU.1, a master transcriptional regulator of  monocyte/macrophage differentiation, regulates 
the expression of mir-424, which in turn inhibits the expression of the transcription factor 
NFI-A. Mir-424 expression has been shown to promote monocyte/macrophage 
differentiation. Thus the two primary transcriptional determinants of myeloid 
differentiation, PU.1 and C/EBP, both involve the activity of microRNAs for lineage 
maturation (Rosa et al., 2007). Thus, miRNAs and myeloid specific transcription factors play 
a critical role in lineage maturation pathways by forming lineage-specific regulatory loops 
(rev in (Gazzar and McCall, 2011)), which if disrupted can lead to the development of 
leukemias. 
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Numerous studies have analyzed the expression of miRNAs in acute myeloid leukemias 
and the resulting miR signatures generated have proved to be helpful in classifying sub-
types of AML and hence the choice of treatment options to be used, as well as in 
determining the efficacy of targeted therapies against AML. For example, Pelosi et al 
analyzed the expression of 12 selected granulocytic signature miRNAs and the impact of all 
trans-retinoic acid  (ATRA)-based therapy in a cohort of acute promyelocytic leukemia 
(APL) patients (Pelosi et al., 2009). APL is a subtype of acute leukemia and is characterized 
by the accumulation of promyelocytes as a result of a chromosomal translocation, most 
commonly involving the retinoic acid alpha receptor and the PML gene in a t(15;17) 
configuration. APL patients respond well to treatment with retinoic acid, a vitamin A 
derivative. The authors  demonstrated using a quantitative real time PCR approach, that 9 
miRNAs were overexpressed while three (mir-107, -342 and Let-7c) were downregulated in 
the blasts of APL patients, compared to normal promyelocytes. They showed in addition, 
that patients successfully treated with ATRA showed down regulation of mir-181b and 
upregulation of mir-15b, -16,-107, -223, -342 and let-7c. Thus, a small subset of miRNAs 
appeared to be differentially regulated in APL  and could be modulated by treatment with 
ATRA. This approach is fast becoming a paradigm in diagnosing and determining the 
efficacy of treatment regimens used in acute myeloid leukemias. 
7. Concluding remarks and perspectives 
Inspite of the fact that there has been a surge of interest in the role of mRNA translational 
regulation in mediating gene expression in myeloid cells in recent times, a great deal of 
work has yet to be done. A general interest in this subject derives its source from the fact 
that cellular pathways commonly deregulated in AML including cell cycle progression, 
proliferation and differentiation are mechanistically tied to mRNA translation. For example, 
several upstream (AKT, TSC1/2) and downstream (eIF4E) mediators of the mTORC1 
pathway are either mutated or activated in AML. Although there has been an intense search 
for therapeutic strategies targeting the mTOR pathway in myeloid cells, much work is yet to 
be done to gain a fundamental understanding of the role of the key players that contribute 
to translation initiation and control in normal and abnormal myeloid cells.   
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